ArticleAnnals of the rheumatic diseases2004
Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).
Article in Annals of the rheumatic diseases, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 3 syntheses or guidelines pooled it, 445 citations in OpenAlex.
- Pooled it
- EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).Annals of the rheumatic diseases · 2007Guideline
- Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review.Annals of the rheumatic diseases · 2006Pooled it
- The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.Arthritis research & therapy · 2018Trial
- Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.Annals of the rheumatic diseases · 2015Trial
- Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study.Arthritis research & therapy · 2008Trial
- High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.Annals of the rheumatic diseases · 2007Trial
- The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.Annals of the rheumatic diseases · 2006Trial
- Comparative analysis of extra-articular manifestations in seronegative and seropositive rheumatoid arthritis patients: a 6-year retrospective study in a tertiary care center.Clinical rheumatology · 2026Article
- Radiographic outcome over 15 years in patients with early rheumatoid arthritis - a BARFOT-study.BMC rheumatology · 2026Article
- Osteoimmunology: Can We Prevent Bone Loss in Rheumatoid Arthritis with Modern Antirheumatic Drugs?Calcified tissue international · 2026Review
- Short- and long-term sustained remission and the role of joint accumulation in early and very early rheumatoid arthritis: a real-world perspective.Journal of rheumatic diseases · 2026Article
- A Tolerogenic Plasmid Inhibits Autoantibody Production Triggered by Immunization With Human Peptidyl Arginine Deiminase 4.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Potential Utility of Combined Salivary Calprotectin and Anti-Cyclic Citrullinated Peptide in Rheumatoid Arthritis Assessment.Diagnostics (Basel, Switzerland) · 2025Article
- Autoantibodies as prognostic markers in rheumatoid arthritis.Journal of translational autoimmunity · 2025Review
- Nano-based Therapeutics for Rheumatoid Arthritis: Recent Patents and Development.Recent patents on nanotechnology · 2025Review
- Clinical Features of ACPA-Negative and ACPA-Positive Variants of Rheumatoid Arthritis.Doklady. Biochemistry and biophysics · 2024Article
- Article
- Review
- Exposure to air pollutants and rheumatoid arthritis biomarkers: A scoping review.Seminars in arthritis and rheumatism · 2024Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the role of anti-cyclic citrullinated peptide antibody (anti-CCP) for the prediction of radiological outcome in patients with early rheumatoid arthritis.
methodsAnti-CCP was assessed at baseline in 379 patients with early rheumatoid arthritis (disease duration <1 year). Radiological joint damage and progression were assessed by Larsen score after two years of follow up (end point) and used as outcome variables. The prognostic value of anti-CCP and other demographic and disease related baseline variables were assessed by univariate and multivariate analyses, including calculation of odds ratios (OR), predictive values, and multiple logistic regression models.
resultsThe presence of anti-CCP was associated with significantly higher Larsen score both at baseline and at end point. Univariate predictor analysis showed that anti-CCP had the highest significant OR for radiological joint damage and progression after baseline Larsen score, followed by rheumatoid factor, erythrocyte sedimentation rate (ESR), C reactive protein, age, smoking status, and sex. In stepwise multiple regression analyses, baseline Larsen score, anti-CCP, and ESR were selected as significant independent predictors of the radiological outcomes.
conclusionsThere is good evidence for an association of anti-CCP with radiological joint changes in rheumatoid arthritis. Anti-CCP is an independent predictor of radiological damage and progression. Though prediction in early rheumatoid arthritis is still far from perfect, the use of anti-CCP in clinical practice should make it easier for rheumatologists to reach judicious treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.